What is the objective response rate for becotatug vedotin in recurrent head and neck cancer?
Becotatug vedotin is an antibody-drug conjugate that targets EGFR. In a phase IIa trial for patients with recurrent or metastatic head and neck squamous cell carcinoma who had already received platinum-based chemotherapy and/or immunotherapy, the objective response rate (ORR) was 20.9% 8. This means about 1 in 5 patients had their tumors shrink or disappear. The response lasted a median of 10.9 months 8.
What the research says
A multicenter phase IIa trial (NCT04868162) tested becotatug vedotin in 67 patients with recurrent or metastatic head and neck squamous cell carcinoma who had progressed after standard treatments 8. Patients received either 2 mg/kg or 2.3 mg/kg every 3 weeks. The overall ORR was 20.9% (14 out of 67 patients), with a 95% confidence interval of 11.9% to 32.6% 8. The median duration of response was 10.9 months, and median progression-free survival was 2.9 months 8. Common side effects included rash, itching, constipation, and anemia 8. This trial provides the only available data on becotatug vedotin's response rate in this setting. Other sources in this set discuss immunotherapy, vaccines, or prognostic markers for head and neck cancer but do not report on becotatug vedotin 146.
What to ask your doctor
- What is the objective response rate for becotatug vedotin in my type of head and neck cancer?
- How does the 20.9% response rate compare with other treatment options I have?
- What are the common side effects of becotatug vedotin, and how are they managed?
- Is becotatug vedotin available through a clinical trial or approved for use in my case?
- What is the expected duration of response and survival with this treatment?
This question is drawn from common patient questions about Oncology and answered using cited medical research. We do not provide individualized advice.